Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03207724 · ClinicalTrials.gov registry record · Phase 1
Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia
A Phase 1 study, sponsored by Andrew Hendifar, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03207724 is a Phase 1 study that has completed, run by Andrew Hendifar, MD. The registered enrollment target is 16 participants.
The verdict
NCT03207724, a Phase 1 study, has completed, sponsored by Andrew Hendifar, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study is being conducted to examine the safety of the investigational drug, Xilonix(™), in addition to standard doses of Onivyde® (nanoliposomal irinotecan) and 5- fluorouracil (5FU)/folinic acid (leucovorin) for pancreatic cancer patients with cachexia. Cachexia is a syndrome that includes involuntary weight loss and physical deterioration that can contribute to poor outcomes of cancer treatment. In other studies, Xilonix has increased lean body mass in advanced cancer patients. This increase could lead to improved weight maintenance and quality of life.
Interventions
- DRUG Xilonix plus Onivyde and 5FU
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2017-10-16 |
| Est. Completion | 2020-10-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03207724
The ClinicalTrials.gov registry entry for NCT03207724 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Andrew Hendifar, MD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Xilonix plus Onivyde and 5FU is the first listed.
NCT03207724 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03207724 about?
NCT03207724 is a clinical study titled "Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia". This study is being conducted to examine the safety of the investigational drug, Xilonix(™), in addition to standard doses of Onivyde® (nanoliposomal irinotecan) and 5- fluorouracil (5FU)/folinic acid (leucovorin) for pancreatic cancer patients with cachexia. Cachexia is a syndrome that includes inv...
What is the current status of trial NCT03207724?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2017-10-16. Estimated completion is 2020-10-27.
What interventions are being tested in trial NCT03207724?
The interventions under investigation include: Xilonix plus Onivyde and 5FU (DRUG).
Who is sponsoring clinical trial NCT03207724?
This trial is sponsored by Andrew Hendifar, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.